Initial-State Interactions in the Unpolarized Drell-Yan Process

We show that initial-state interactions contribute to the $\cos 2 \phi$ distribution in unpolarized Drell-Yan lepton pair production $p p$ and $p \bar p \to \ell^+ \ell^- X$, without suppression. The asymmetry is expressed as a product of chiral-odd distributions $h_1^\perp(x_1,\bm{p}_\perp^2)\times \bar h_1^\perp(x_2,\bm{k}_\perp^2)$, where the quark-transversity function $h_1^\perp(x,\bm{p}_\perp^2)$ is the transverse momentum dependent, light-cone momentum distribution of transversely polarized quarks in an {\it unpolarized} proton. We compute this (naive) $T$-odd and chiral-odd distribution function and the resulting $\cos 2 \phi$ asymmetry explicitly in a quark-scalar diquark model for the proton with initial-state gluon interaction. In this model the function $h_1^\perp(x,\bm{p}_\perp^2)$ equals the $T$-odd (chiral-even) Sivers effect function $f^\perp_{1T}(x,\bm{p}_\perp^2)$. This suggests that the single-spin asymmetries in the SIDIS and the Drell-Yan process are closely related to the $\cos 2 \phi$ asymmetry of the unpolarized Drell-Yan process, since all can arise from the same underlying mechanism. This provides new insight regarding the role of quark and gluon orbital angular momentum as well as that of initial- and final-state gluon exchange interactions in hard QCD processes.Comment: 22 pages, 6 figure

Investigating the origins of transverse spin asymmetries at RHIC

We discuss possible origins of transverse spin asymmetries in hadron-hadron collisions and propose an explanation in terms of a chiral-odd T-odd distribution function with intrinsic transverse momentum dependence, which would signal a correlation between the transverse spin and the transverse momentum of quarks inside an unpolarized hadron. We will argue that despite its conceptual problems, it can account for single spin asymmetries, for example in p + p(transversely polarized) -> pion + X, and at the same time for the large cos(2 phi) asymmetry in the unpolarized Drell-Yan cross section, which still lacks understanding. We use the latter asymmetry to arrive at a crude model for this function and show explicitly how it relates unpolarized and polarized observables in the Drell-Yan process, as could be measured with the proton-proton collisions at RHIC. Moreover, it would provide an alternative method of accessing the transversity distribution function h_1. For future reference we also list the complete set of azimuthal asymmetries in the unpolarized and polarized Drell-Yan process at leading order involving T-odd distribution functions with intrinsic transverse momentum dependence.Comment: 14 pages, Revtex, 4 Postscript figures, uses aps.sty, epsf.sty, Minor mistakes in cross sections corrected, Conclusions are unaffecte

Prospects for e+e- physics at Frascati between the phi and the psi

We present a detailed study, done in the framework of the INFN 2006 Roadmap, of the prospects for e+e- physics at the Frascati National Laboratories. The physics case for an e+e- collider running at high luminosity at the phi resonance energy and also reaching a maximum center of mass energy of 2.5 GeV is discussed, together with the specific aspects of a very high luminosity tau-charm factory. Subjects connected to Kaon decay physics are not discussed here, being part of another INFN Roadmap working group. The significance of the project and the impact on INFN are also discussed. All the documentation related to the activities of the working group can be found in http://www.roma1.infn.it/people/bini/roadmap.html.Comment: INFN Roadmap Report: 86 pages, 25 figures, 9 table

Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trial

Background: Febuxostat and allopurinol are urate-lowering therapies used to treat patients with gout. Following concerns about the cardiovascular safety of febuxostat, the European Medicines Agency recommended a post-licensing study assessing the cardiovascular safety of febuxostat compared with allopurinol. Methods: We did a prospective, randomised, open-label, blinded-endpoint, non-inferiority trial of febuxostat versus allopurinol in patients with gout in the UK, Denmark, and Sweden. Eligible patients were 60 years or older, already receiving allopurinol, and had at least one additional cardiovascular risk factor. Those who had myocardial infarction or stroke in the previous 6 months or who had severe congestive heart failure or severe renal impairment were excluded. After a lead-in phase in which allopurinol dose was optimised towards achieving a serum urate concentration of less than 0·357 mmol/L (<6 mg/dL), patients were randomly assigned (1:1, with stratification according to previous cardiovascular events) to continue allopurinol (at the optimised dose) or start febuxostat at 80 mg/day, increasing to 120 mg/day if necessary to achieve the target serum urate concentration. The primary outcome was a composite of hospitalisation for non-fatal myocardial infarction or biomarker-positive acute coronary syndrome; non-fatal stroke; or cardiovascular death. The hazard ratio (HR) for febuxostat versus allopurinol in a Cox proportional hazards model (adjusted for the stratification variable and country) was assessed for non-inferiority (HR limit 1·3) in an on-treatment analysis. This study is registered with the EU Clinical Trials Register (EudraCT 2011-001883-23) and ISRCTN (ISRCTN72443728) and is now closed. Findings: From Dec 20, 2011, to Jan 26, 2018, 6128 patients (mean age 71·0 years [SD 6·4], 5225 [85·3%] men, 903 [14·7%] women, 2046 [33·4%] with previous cardiovascular disease) were enrolled and randomly allocated to receive allopurinol (n=3065) or febuxostat (n=3063). By the study end date (Dec 31, 2019), 189 (6·2%) patients in the febuxostat group and 169 (5·5%) in the allopurinol group withdrew from all follow-up. Median follow-up time was 1467 days (IQR 1029–2052) and median on-treatment follow-up was 1324 days (IQR 870–1919). For incidence of the primary endpoint, on-treatment, febuxostat (172 patients [1·72 events per 100 patient-years]) was non-inferior to allopurinol (241 patients [2·05 events per 100 patient-years]; adjusted HR 0·85 [95% CI 0·70–1·03], p<0·0001). In the febuxostat group, 222 (7·2%) of 3063 patients died and 1720 (57·3%) of 3001 in the safety analysis set had at least one serious adverse event (with 23 events in 19 [0·6%] patients related to treatment). In the allopurinol group, 263 (8·6%) of 3065 patients died and 1812 (59·4%) of 3050 had one or more serious adverse events (with five events in five [0·2%] patients related to treatment). Randomised therapy was discontinued in 973 (32·4%) patients in the febuxostat group and 503 (16·5%) patients in the allopurinol group. Interpretation: Febuxostat is non-inferior to allopurinol therapy with respect to the primary cardiovascular endpoint, and its long-term use is not associated with an increased risk of death or serious adverse events compared with allopurinol. Funding: Menarini, Ipsen, and Teijin Pharma Ltd

The importance of juveniles in modelling growth: butterflyfish at Lizard Island

I established and fitted von Bertalanffy growth functions to size-at-age data for four species of chaetodontids at Lizard Island. Special emphasis on juveniles provided detailed information of the early growth period. All four species demonstrated rapid initial growth achieving an average of 92% of maximum theoretical size in the first 2thinspyears. I used various constraints of the theoretical age at length zero (t0) in an analysis of both complete data sets and data sets using only adult fish. An unconstrained value of t0 resulted in the best-fit (maximum r2) curve when juveniles were included. When excluding juveniles, it was necessary to constrain t0 to an approximate settling size to most closely represent the growth of the species